The Use of Vasoactive Drugs in the Treatment of Male Erectile Dysfunction: Current Concepts

• Main Authors: George T. Kedia, Stefan Ückert, Dimitrios Tsikas, Armin J. Becker, Markus A. Kuczyk, Andreas Bannowsky
• Format: Article
• Language: English
• Published: MDPI AG 2020-09-01
• Series: Journal of Clinical Medicine
• Subjects: erectile dysfunction (ED); drug treatment; vasoactive compounds; nitric oxide (NO)/cyclic guanosine monophosphate (cyclic GMP); cyclic adenosine monophosphate (cyclic AMP)
• Online Access: https://www.mdpi.com/2077-0383/9/9/2987

It is widely accepted that disorders of the male (uro)genital tract, such as erectile dysfunction (ED) and benign diseases of the prostate (lower urinary tract symptomatology or benign prostatic hyperplasia), can be approached therapeutically by influencing the function of both the vascular and non-vascular smooth muscle of the penile erectile tissue or the transition zone/periurethral region of the prostate, respectively. As a result of the discovery of nitric oxide (NO) and cyclic guanosine monophosphate (GMP) as central mediators of penile smooth muscle relaxation, the use of drugs known to increase the local production of NO and/or elevate the intracellular level of the second messenger cyclic GMP have attracted broad attention in the treatment of ED of various etiologies. Specifically, the introduction of vasoactive drugs, including orally active inhibitors of the cyclic GMP-specific phosphodiesterase (PDE) 5, has offered great advantage in the pharmacotherapy of ED and other diseases of the genitourinary tract. These drugs have been proven efficacious with a fast on-set of action and an improved profile of side-effects. This review summarizes current strategies for the treatment of ED utilizing the application of vasoactive drugs via the oral, transurethral, topical, or self-injection route.